...
首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >CLINICAL PHARMACIST ASSESSMENT OF MONITORING AND RESOLVING THE DRUG-RELATED PROBLEMS IN BIPOLAR DISORDER PATIENTS: A PROSPECTIVE, OBSERVATIONAL STUDY AT TERTIARY CARE TEACHING HOSPITAL
【24h】

CLINICAL PHARMACIST ASSESSMENT OF MONITORING AND RESOLVING THE DRUG-RELATED PROBLEMS IN BIPOLAR DISORDER PATIENTS: A PROSPECTIVE, OBSERVATIONAL STUDY AT TERTIARY CARE TEACHING HOSPITAL

机译:监测和解决双歧疾病患者药物相关问题的临床药师评估:对三级护理教学医院的观察性前瞻性研究

获取原文
           

摘要

Background: Bipolar disorder is a chronic mental illness due to a different interval of manic and depressive phase, the patient may become more prone to DRP, which interfere with the patients’ health outcome. Hence, clinical pharmacist can contribute to managing the DRP through proper pharmaceutical care intervention. Method/Design: A prospective, observational study had been done with 286 participants to assess, monitor, and resolve the DRP through Clinical Pharmacist intervention. Patients with Bipolar disorder, aged 18 to 65, included in the study except for the patient with other comorbid condition, lactating mothers, and pregnant women. Results: DRP in between, all the patients were observed, of which 70.9 % were drug-drug interaction followed by 29.1% ADR. The two major causes of DRP were at drug/dose selection level 95.5%, followed by a drug use process level 4.5%. Pharmacist intervention has been proposed at prescriber level, of which majority of interventions 52.7% had been accepted by the prescriber. Conclusion: In our study, the majority of DRP 64.7%, had been resolved due to the clinical pharmacist intervention, which shows that participation of clinical pharmacist in psychiatric setting may help to resolve the DRP and integrate the health care delivery system.
机译:背景:躁郁症是一种慢性精神疾病,由于躁狂和抑郁期的间隔不同,患者可能更容易接受DRP,从而干扰患者的健康状况。因此,临床药剂师可以通过适当的药物护理干预措施来管理DRP。方法/设计:前瞻性观察研究已与286名参与者进行了评估,以通过临床药剂师的干预来评估,监测和解决DRP。除其他合并症患者,哺乳期母亲和孕妇外,本研究包括18至65岁的躁郁症患者。结果:在所有患者之间均观察到DRP,其中70.9%为药物相互作用,其次为29.1%ADR。 DRP的两个主要原因是药物/剂量选择水平为95.5%,其次是药物使用过程水平为4.5%。已经在处方者级别提出了药剂师干预措施,其中大多数干预措施52.7%已被处方者接受。结论:在我们的研究中,由于临床药剂师的干预,大部分DRP得以解决,占64.7%,这表明临床药剂师参与精神病治疗可能有助于解决DRP和整合医疗服务体系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号